Global Report; 221 Pages
Mesenchymal stem cells (MSCs) are the most utilized cell type within the regenerative medicine industry. To support this rapidly expanding marketplace, BioInformant has released a 210-page global strategic report revealing trend rate data for MSC market, including rates of MSC patents, grants, scientific publications, and clinical trials, as well as social analytics that identify online behavior related to MSCs.
The report describes the current status of mesenchymal stem cell (MSC) research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and uses of MSCs in cell therapy. It explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 73 leading competitors within the MSC marketplace.
For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies. A prominent trend within the regenerative medicine industry is a growing interest among “big pharma” in cell therapy companies. At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline. Pharmaceutical companies are now aggressively investing in cell therapy companies, with companies developing MSC therapeutics representing promising candidates for collaboration, investment, or acquisition.
Because MSC therapy is an integrated component of Advanced Therapy Medicinal Products (ATMPs), this market report also provides an introduction to ATMPs.
Burgeoning Market for Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types.
In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications.
Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth. Additionally, MSCs well-suited for use in the exponential growth area of 3D printing, because of their capacity to form structural tissues.
Growing attention is now being given to manufacturing technologies to support commercial-scale production of MSCs.
Numerous market competitors are also exploring commercialization strategies for MSC-derived exosomes, because exosomes represent a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.
As the most common stem cell type being used in regenerative medicine, there is substantial potential for growth within the MSC market. Today, there are more than 40,000 scientific publications published about the cell type, more than 800 clinical trials underway worldwide, and Google Trend data reveals that MSC searches are more than twice as common as the next most common adult stem cell type.
Produced for companies involved with mesenchymal stem cell (MSC) products and technologies, this global report reveals critical insights for competing within the global marketplace. Based in Washington, DC, BioInformant is first and only market research firm to specialize in the stem cell industry. Unlike other publishers that hire analysts from foreign countries, BioInformant is an American-based company with more than 10 years of experience with tracking the stem cell market (2006 to present).
BioInformant compiled this global strategic report using primary interviews with more than 70 individuals from across the stem cell industry.
In total over the past 10 years, BioInformant has conducted more than 1,000 interviews from across the stem cell industry, including representatives from Cynata Therapeutics (first company to bring a iPSC-derived MSC therapeutic product into a clinical trial), Pluristem Therapeutics (developing placenta-derived, mesenchymal-like adherent stromal cells called PLX cells), RoosterBio (leading manufacturer of therapeutic-grade MSCs at commercial-scale), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world’s leading provider of MSC therapies for orthopedic applications), and many more.
The report also incorporates secondary findings from SEC filings, company websites, press releases, investor presentations, government policy documents, Google Trends, and Google Adwords.
Claim this report to:
- Identify the market segments that compose the MSC industry
- Reveal the key market players competing in each niche
- Identify opportunities for MSC product development
- Access market size determinations for the MSC market with projections through 2022
- Exploit emerging opportunities within the MSC marketplace
View Table of Contents: Coming Soon
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
Get immediate access to your product as a PDF download; printing rights allowed.
Of course, your investment is covered by a Greater than 100% Money Back Guarantee.
Act soon, because this offer is only available for a limited-time.
 PubMed.gov Search; Date: 01/14/2017. Search terms: “mesenchymal stem cell” OR “mesenchymal stem cells” OR “mesenchymal stromal cell” OR “mesenchymal stromal cells”. Link.
 ClinicalTrials.gov Search; Date: 01/14/2017. Search terms: “mesenchymal stem cell” OR “mesenchymal stem cells” OR “mesenchymal stromal cell” OR “mesenchymal stromal cells”. Link.
 Google Trends Search; Date: 01/14/2017. Search Terms Compared: “mesenchymal stem cells” vs. “hematopoietic stem cells” vs. “neural stem cells”. Link.